ERCC1 and nasopharyngeal carcinoma: In conclusion, this study used a pathway approach to demonstrate that genetic variations within MPO, MDM2, ERCC1 and ABCB1 were associated with survival in patients with locoregionally advanced NPC treated with cisplatin- and 5-FU-based CRT.